By integrating in vitro 2CT screen data from the control group and the ACT dataset from melanoma lines derived from pre-treatment clinical samples, we observed that knocking out Prmt1 or Ripk1 can downregulate the expression of a set of genes associated with poor clinical outcomes in melanoma patients treated by ACT (Figure 4A). This evidence concerns the gene RIPK1 and melanoma.